{"id":2865,"date":"2020-03-25T07:30:00","date_gmt":"2020-03-25T07:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/"},"modified":"2020-03-25T07:30:00","modified_gmt":"2020-03-25T07:30:00","slug":"xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/","title":{"rendered":"XVIVO Perfusion advances the date for submission of the January-March 2020 interim report"},"content":{"rendered":"<p><span><span>In order to provide information on XVIVO Perfusion&#39;s results and financial position for the period January-March 2020 as soon as possible, the company has decided to advance the submission of the report. New report date is Thursday 9 April at. 7.30 a.m. A conference call will be held on <span>Thursday, April 9 at. 11.30 a.m.<\/span><\/span><\/span><\/p>\n<p><span><span><span><span>March 25, 2020<\/span><\/span><\/span><br \/>\n<span><span>Gothenburg<\/span><\/span><br \/>\n<span><span>XVIVO Perfusion AB (publ)<\/span><\/span><\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span><span>For further information please contact:<\/span><\/span><\/p>\n<p><span><span>Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com<br \/>\nMagnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span><\/span><br \/>\n<span><span>For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/span><\/p>\n<p><span><span>This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.\u00a0\u00a0The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on March 25, 2020.<\/span><\/span><\/p>\n<p><span><span>This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>In order to provide information on XVIVO Perfusion&#39;s results and financial position for the period January-March 2020 as soon as&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2865","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-calendar","mfn-news-tag-mfn"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO Perfusion advances the date for submission of the January-March 2020 interim report - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion advances the date for submission of the January-March 2020 interim report - XVIVO\" \/>\n<meta property=\"og:description\" content=\"In order to provide information on XVIVO Perfusion&#039;s results and financial position for the period January-March 2020 as soon as...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\\\/\",\"name\":\"XVIVO Perfusion advances the date for submission of the January-March 2020 interim report - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2020-03-25T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion advances the date for submission of the January-March 2020 interim report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion advances the date for submission of the January-March 2020 interim report - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion advances the date for submission of the January-March 2020 interim report - XVIVO","og_description":"In order to provide information on XVIVO Perfusion&#39;s results and financial position for the period January-March 2020 as soon as...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/","name":"XVIVO Perfusion advances the date for submission of the January-March 2020 interim report - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2020-03-25T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-advances-the-date-for-submission-of-the-january-march-2020-interim-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion advances the date for submission of the January-March 2020 interim report"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}